Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
For a patient with locally advanced rectal cancer, would positive ctDNA after total neoadjuvant therapy affect your management?
Would you consider additional chemotherapy post-operatively?
Related Questions
Is there strong evidence to use TMB found in circulating tumor DNA to guide the use of ICI in metastatic colon cancer?
For patients with large, partially or nearly obstructing rectal cancers, how do you sequence TNT in order to avoid complete obstruction and surgical diversion?
Should immunotherapy be added to standard of care neoadjuvant chemotherapy in borderline resectable MSI-H adenocarcinoma of pancreas?
In which patients with early stage rectal cancer treated according to the PROSPECT paradigm do you recommend adjuvant chemotherapy?
Would you treat a patient with a pancreatic head mass based on common bile duct brushings suggestive of malignancy, with repeated negative EUS biopsy?
For an incidental cholangiocarcinoma found at time of liver transplant (done for HCC or other reason) in the explanted liver, do you give adjuvant chemotherapy and if so which regimen?
Do you treat patients with resected adenocarcinoma of the intrapancreatic bile duct along a biliary paradigm or pancreatic paradigm?
How would you approach an MSI-H HPV+ T2 N1 squamous cell carcinoma of the anus?
Would you offer adjuvant 5-FU-based therapy for a patient with adenocarcinoma involving the ischiorectal fossa thought to be tailgut cyst adenocarcinoma who achieved a pCR to 5-FU + RT followed by surgery?
In which situations do you omit the 5FU bolus in FOLFOX or FOLFIRI?